How to Help Your Patients Save Money on Entecavir: A Provider's Guide to Savings Programs

Entecavir is a lifelong treatment for most patients with chronic hepatitis B. Cost-related non-adherence is one of the leading causes of hepatitis B treatment failure—and treatment failure carries severe clinical consequences, including risk of hepatic decompensation and hepatocellular carcinoma progression. As prescribers, understanding the savings landscape for entecavir and proactively connecting patients with financial resources is a core part of effective HBV management.

This guide is designed for hepatologists, gastroenterologists, infectious disease specialists, and primary care providers who prescribe entecavir. It covers the full savings landscape: discount cards, patient assistance programs, insurance strategies, and how to route patients to the right resource based on their coverage situation.

Understanding the Cost Landscape for Entecavir in 2026

The retail (cash) price of generic entecavir without insurance or discount cards is approximately $1,126 per 30-tablet supply (0.5 mg). This is driven by the pharmacy's contracted wholesale price—not manufacturing cost—as generic entecavir's actual production cost is low.

With appropriate discount tools:

• GoodRx: $13–$31 for 30 tablets at major retail chains (CVS, Walgreens, Walmart)
• SingleCare: As low as $11.06 for 30 tablets (0.5 mg) at Walmart, Kroger, and Walgreens
• Medicare Part D: Typically Tier 4 (specialty tier); copay ranges from $15 to $836 depending on plan and benefit phase
• Commercial insurance: Usually Tier 2–3 for generic; typical copay $10–$60 for most plans. Prior authorization may apply.

Screening Patients for Cost-Related Non-Adherence

At every visit, consider using a simple one-question screen: "In the past 3 months, have you ever taken less medication than prescribed, or skipped refills, because of cost?" Research consistently shows that patients underreport cost-related non-adherence unless directly asked. For a drug like entecavir, even brief interruptions carry significant risk.

Resource 1: GoodRx and SingleCare Discount Cards

For uninsured patients and patients whose insurance copay exceeds the discount card price, GoodRx and SingleCare can reduce the cost of generic entecavir to $11–$31 per 30-tablet supply. Importantly, these cards can be used instead of (not with) insurance.

Practical step for practices: Print a single-page handout with QR codes for GoodRx and SingleCare, and include it in your new patient hepatitis B packet. This eliminates one barrier at the point of first prescription.

Resource 2: Patient Assistance Programs (PAPs)

For patients with insurance who still face high out-of-pocket costs, or for specific populations with limited income, PAPs may provide significant financial relief:

• Good Days Patient Assistance Program: 1-877-968-7233 | mygooddays.org. Requires: active insurance, chronic hepatitis B diagnosis. Application via phone or online. Enrollment typically within 2–5 business days.
• NeedyMeds (needymeds.org): Comprehensive directory of manufacturer and non-profit PAPs. Useful for patients on generic entecavir where manufacturer programs may be limited.
• RxAssist (rxassist.org): Another comprehensive PAP directory. Can search by drug name to find active assistance programs.

Resource 3: Medicare Part D Optimization

Medicare patients face unique challenges with entecavir's Tier 4 placement. Key strategies:

• Formulary exception request: Providers can submit a formulary exception request to move entecavir from Tier 4 to a lower tier. Document the medical necessity of entecavir specifically (resistance concerns, prior drug failures, etc.).
• Open enrollment plan comparison: During Medicare open enrollment (October 15–December 7), patients should compare plans specifically on entecavir tier placement and annual cost. The Medicare Plan Finder at medicare.gov allows drug-specific comparisons.
• GoodRx vs. Medicare comparison: For patients whose Medicare copay exceeds the GoodRx price ($13–$31), the discount card may be cheaper. Advise patients to compare both at each refill—prices change as plans adjust formularies.

Resource 4: 340B Programs for Qualifying Health Centers

Federally Qualified Health Centers (FQHCs), Ryan White Clinics, and other 340B-covered entities can access entecavir at significantly reduced prices under the federal 340B Drug Pricing Program. If your practice serves a patient population eligible for 340B services, this can substantially reduce the cost burden for uninsured or underinsured HBV patients.

Building Cost-Access into Your Practice Workflow

Consider these practice-level improvements:

1. At the first visit, document insurance status and provide a discount card handout to all patients regardless of insurance
2. Train front-desk and nursing staff to recognize when patients express concerns about medication costs and to route them to a social worker or financial navigator
3. Prescribe 90-day supplies whenever possible to reduce how often patients face refill costs and access barriers
4. Coordinate with specialty pharmacies for prior authorization support—many have dedicated PA teams that can handle paperwork on your behalf

For help with medication access (not just cost), consider recommending medfinder to patients who struggle to find pharmacies with entecavir in stock. See also: How to Help Your Patients Find Entecavir in Stock.